CWP291

News alerts, weekly reports and conference planners

Company:

JW Pharma

Drug class:

Wnt antagonist

‹

›

2ms

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov)

P1/2, N=15, Terminated, JW Pharmaceutical | Phase classification: P1b/2a --> P1/2 | N=45 --> 15 | Trial completion date: Oct 2022 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Aug 2025; business/strategic reason

2 months ago

Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date

cytarabine • CWP291

over3years

Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer. (PubMed, Front Oncol)

Noticeably, CWP232291 could also s suppress the growth of cisplatin-resistant cell lines and ovarian cancer patient-derived organoids. Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer.

over 3 years ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1)

cisplatin • CWP291

over3years

Smad4 and p53 synergize in suppressing autochthonous intestinal cancer. (PubMed, Cancer Med)

Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway.

over 3 years ago

Journal

BCL2L1 (BCL2-like 1) • SMAD4 (SMAD family member 4)

TP53 mutation

CWP291

almost6years

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. (PubMed, Blood Adv)

Future studies will explore CWP291, with a mechanism of action aimed at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. This trial was registered at www.clinicaltrials.gov as #NCT01398462.

almost 6 years ago

Clinical • P1 data • Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1)

CWP291